The Food and Drug Administration on Wednesday approved updated COVID-19 vaccines from Pfizer and Moderna for the upcoming respiratory virus season, but limited eligibility to seniors and people at heightened risk of severe illness, marking a shift from broader recommendations in previous years, The Hill reported.

The FDA cleared Moderna’s updated Spikevax shot for adults 65 and older, as well as individuals 6 months through 64 with at least one underlying condition linked to serious COVID-19 outcomes.

Pfizer’s Comirnaty vaccine received approval for the same senior group and for those ages 5 to 64 with qualifying health conditions.

Read more at Newsmax© 2025 Newsmax. All rights reserved.